Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 28, 2026

Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback

View original at finance.yahoo.com

Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback Never miss an important update on your stock portfolio and cut through the noise…

Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

AstraZeneca currently scores 3 out of 6 on Simply Wall St's valuation checks, meaning the company screens as undervalued on half of the tests used
60% confidence
AstraZeneca is undervalued by 41.1% according to Discounted Cash Flow analysis
60% confidence
The DCF model points to an estimated intrinsic value of £242.86 per share compared with the current share price of £143.02, implying shares trade at a 41.1% discount to fair value
60% confidence

Data points we hold from this source

AstraZeneca AB · free cash flow projected	20.2 USD
AstraZeneca AB · intrinsic value per share	242.86 GBP
AstraZeneca AB · stock return 1 month	-6.0 percent
AstraZeneca AB · stock return 1 week	2.9 percent
AstraZeneca AB · stock return 1 year	27.5 percent
AstraZeneca AB · stock return 3 year	35.2 percent
AstraZeneca AB · stock return 5 year	121.6 percent